Article Text

Download PDFPDF

AB0910 Long-term golimumab retention rate in patients with psoriatic arthritis. is concomitant dmard important?
  1. B. Serrano-Benavente1,2,
  2. C.M. González-Fernández1,2,
  3. L. Valor1,
  4. I. Janta1,
  5. R.D. González-Benítez1,
  6. C. Sáenz Tenorio1,
  7. J.C. Nieto-González1,
  8. J.G. Ovalles-Bonilla1,
  9. J. Martínez-Barrio1,
  10. M. Correyero Plaza1,
  11. L. García-Montoya1,
  12. F.J. López-Longo1,2,
  13. I. Monteagudo Saez1
  1. 1Rheumatology, Hospital General Universitario Gregorio Marañón
  2. 2Faculty of Medicine, Universidad Complutense de Madrid, Madrid, Spain


Background The efficacy of Golimumab treatment in psoriatic arthritis (PsA) patients has been widely documented.

Objectives The aim of this study was to analyse the long-term retention rate of golimumab and to identify independent predictors of drug retention in patients with PsA including concomitant synthetic disease-modifying antirheumatic drugs (sDMARD)

Methods Prospective monocentric cohort of PsA patients treated with golimumab according to clinical practice. Study was approved by local Ethics Committee. Demographic and clinical variables were analysed with Cox proportional hazard regression model.

Results 48 patients were included, 20/48 (41.7%) oligoarticular, 19/48 (39.6%) polyarticular and 9/48 (18.7%) with peripheral and axial PsA. The baseline characteristics of the patients are shown in table 1.

Abstract AB0910 – Table 1

Baseline demographic and clinical characteristics of the patients.

Follow-up time was 89.25 patients-year. Mean survival time was 40.3 months (95% CI: 32.0–48.5). Age, mean evolution time and previous biological use were significant in the univariate analysis. Concomitant sDMARD had no influence on golimumab retention rate (HR: 1.3; 95% CI: 0.5–3.2; p: 0.6). Figure 1. When golimumab was used as first or second biologic treatment, it had a better retention rate than when it was used as third or fourth, but did not reach statistical significance (HR: 2.3; IC 95%: 0.8–6.2; p=0.1). 18/48 patients (37.5%) withdrew golimumab treatment. 13/18 (72.2%) due to lack of efficacy, 1/18 (0.6%) due to adverse events and 4/18 (22.2%) due to other reasons.

Abstract AB0910 – Figure 1

Golimumab retention rate and concomitant DMARD

Conclusions Real-world Golimumab retention rate in patients with PsA was good and did not depend on concomitant treatment with sDMARD. When used as first or second biologic, Golimumab retention rate tended to be better.

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.